In this issue:
Mechanisms of antigen escape from targeted immunotherapies
Promising activity for mezigdomide plus dexamethasone in RRMM
MagnetisMM-3: elranatamab induces deep responses in RRMM
Stem cell boost rescues multilineage haematopoesis after CAR T-cell therapy
Poor long-term outcomes after alloSCT
Low risk of SPM with long-term lenalidomide treatment
OPTIMUM: Dara-CVRd delays progression of ultra-high-risk disease
MASTER finds that MRD status can guide treatment discontinuation in most patients
Birtamimab plus standard of care in light-chain amyloidosis
Please login below to download this issue (PDF)